Mayo Clinic Pharmacy Grand Rounds

Pharmacy’s Fantastic when the Marrows Aplastic: Pharmacologic Management of Aplastic Anemia

Devon S. Stonerock, PharmD (@DevonStoneRx) describes the underlying pathophysiology driving the development and progression of aplastic anemia, outlines treatment options based on patient specific factors and recognizes key toxicities, drug interactions, and administration considerations for patients receiving immunosuppressive therapy.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

It’s in the Genes: Identification and Treatment of ESBL-E

Sarah A. Chase, PharmD identifies the most common ESBL-producing bacteria and common ESBL resistance genes, recognizes the use and limitations in using phenotypic and genotypic data to identify potential ESBL-E organisms and discusses clinical trial data and IDSA guidance to assist in the selection of appropriate antimicrobials for the treatment of ESBL-E infections .

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Early Multimodal Vasopressors in Septic Shock: When is it Time for Full-Court Press(ors)?

Kyle A. Hess, PharmD (@KyleHessPHarmD) describes the rationale for early use of vasopressors with multiple mechanisms of action in patients with septic shock, reviews the literature examining the early initiation of vasopressin in patients with septic shock and identifies patient characteristics associated with positive response to angiotensin II.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

The R(igh)T Way or the Highway: Pharmacologic Management of Radiation Therapy (RT) Toxicities

Divya A. Khandekar, PharmD, MS (@pharmdiv) discusses the basic principles of radiation therapy in the treatment of cancer, describes the etiology and pathophysiology of toxicities caused by radiation therapy and identifies which pharmacological treatments for radiation toxicity management are evidence-based.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

The Unit that Never Sleeps: Pharmacologic Sleep Agents for Critically Ill Patients

Nikitha Yagnala, PharmD (@nikithayagnala) recognizes the physiologic consequences of sleep disturbances in critically ill patients, discusses the mechanisms of sleep promotion for pharmacologic sleep agents and outlines appropriate utilization of pharmacologic sleep agents in critically ill patients.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Fluid Stewardship in the ICU: The Rush to De-resuscitate

Andrew J. Jatis, PharmD (Twittter:@jatis_rx) Identifies adverse consequences of fluid overload in critically ill patients, summarizes literature assessing the efficacy and safety of fluid stewardship strategies and generates patient-specific plans for fluid management based on available evidence.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

A CYmPle Matter – CYP2C19 Polymorphisms and P2Y12 Inhibitor Selection in Ischemic Stroke

Jo Ann Leal, PharmD (Twitter: @jojopharmd) describes the implications of various CYP2C19 phenotypes on clopidogrel metabolism and activity, analyzes the available literature evaluating outcomes of clopidogrel versus ticagrelor in ischemic stroke patients based on CYP2C19 metabolizer status and selects a preferred antiplatelet agent and dose for secondary prevention of ischemic stroke given patient specific pharmacogenomic information.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Pediatric Updates on Transplant Associated-Thrombotic Microangiopathy (TA-TMA)

KaShena L. Kennedy, PharmD (Twitter: @KaShenaKennedy) reviews and identifies the pathophysiology, clinical manifestations, and diagnostic criteria for TA-TMA in pediatric patients, differentiates risk factors associated with TA-TMA and discusses prophylactic treatment in pediatric patients and explores treatment and emerging therapy options of TA-TMA in pediatric patients.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Time for a Heart-to-Heart: ADAPTing Antithrombotic Therapy Post-TAVR

Aeryana Beaudrie-Nunn, PharmD (Twitter: @ABeaudrieRx) identifies the rationale for antithrombotic therapy following TAVR, reviews the utility of direct oral anticoagulants after TAVR considering recent clinical trial data and defines the patient context where direct oral anticoagulant use following TAVR is most appropriate.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

Dual Antiplatelet Therapy Following PCI: Choosing a SMART-DATE to STOP-DAPT

Kyle A. Hess, PharmD (Twitter: @KyleHessPharmD ) describes current guideline recommendations for duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention, compares and contrasts strategies for antiplatelet regimens for reduced duration DAPT and selects an appropriate duration of therapy when utilizing shortened DAPT.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.